NakamotoH.Encapsulating peritoneal sclerosis—a clinician's approach to diagnosis and medical treatment.Perit Dial Int2005; 25(Suppl 4): S30–8.
2.
De FreitasD., JordaanA., WilliamsR., AlderdiceJ., CurwellJ., HurstH.Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis.Perit Dial Int2008; 28: 271–6.
3.
KawanishiH., KawaguchiY., FukuiH., HaraS., ImadaA., KuboH.Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.Am J Kidney Dis2004; 44: 729–37.
4.
KorteM., YoM., BetjesM., FierenM., SaaseJ., BoerW.Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation.Nephrol Dial Transplant2007; 22: 2412–14.
5.
MoustafellosP., HadjianastassiouV., RoyD., VelzeboerN., ManiakynN., VaidyaA.Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation.Transplant Proc2006; 38: 2913–14.
6.
AhmadM., ShahH., PliakogiannisT., OreopoulosD.G.Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.Int Urol Nephrol2007; 39: 299–312.
7.
Yanez-MoM., Lara-PezziE., SelgasR., Ramirez-HuescaM., Dominguez-JimenezC., Jimenez-HeffernanJ.Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells.N Engl J Med2003; 348: 403–13.
KhannaA., PlummerM., BromberekC., BresnahanB., HariharanS.Expression of TGF-β and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.Kidney Int2002; 62: 2257–63.
10.
KawanishiH., MoriishiM., IdeK., DohiK.Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis.Perit Dial Int2008; 28(Suppl 3): S205–10.
11.
LafranceJ., LetourneauI., OuimetD., BonnardeauxA., LeblancM., MathieuN.Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy.Am J Kidney Dis2008; 51: e7–10.
12.
Van BommelE., HendrikszT., HuiskesA., ZeegersA.Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis.Ann Intern Med2006; 144: 101–6.
13.
TurnerM.W., HollemanJ.H.Successful therapy of sclerosing peritonitis.Semin Dial1992; 5: 316.
14.
MargettsP.J., BonniaudP., LiuL., HoffC., HolmesC., West-MaysJ.Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum.J Am Soc Nephrol2005; 16: 425–36.
15.
De VrieseA., TiltonR., MortierS., LameireN.Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia.Nephrol Dial Transplant2006; 21: 2549–55.
16.
PayneW.G., KoF., AnspaughS., WheelerC., WrightT., RobsonM.Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma.Ann Plast Surg2006; 56: 301–5.
17.
EltoumM., WrightS., AtchleyJ., MasonJ.Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen.Perit Dial Int2006; 26: 203–6.
18.
SummersA.M., ClancyM.J., SyedF., HarwoodN., BrenchleyP., AugustineT.Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.Kidney Int2005; 68: 2381–8.
19.
Del PesoG., BajoA., GilF., AguileraA., RosS., CosteroO.Clinical experience with tamoxifen in peritoneal fibrosing syndromes.Adv Perit Dial2003; 19: 32–5.
20.
SelgasR., AguileraA., BajoA., LoureiroJ., Del PesoG., AroeiraL.Effects of tamoxifen on epithelial-to-mesenchymal transition (EMT), fibrosis and angiogenesis of mesothelial cells [Abstract].J Am Soc Nephrol2006; 17: 758A.
21.
AllariaP., GiangrandeA., GandiniE., PisoniI.Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent?J Nephrol1999; 12: 395–7.
22.
PollockC.Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis.Semin Dial2003; 16: 406–10.
23.
EvrenkayaT.R., AtasoyuE.M., UnverS., BasekimC., BalogluH., TulbekM.Y.Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant2004; 19: 2423–4.
24.
KorzetsA., OriY., ZevinD., ChagnacA., HermanM., Rozen-ZviB.A worrying thought—could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis?Nephrol Dial Transplant2006; 21: 2975–8.
25.
MesquitaM., GuillaumeM.P., DratwaM.First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis.Clin Drug Invest2007; 27: 727–9.
26.
ThirunavukarasuT., SaxenaR., AnijeetH., PaiP., WongC.F.Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature.Ren Fail2007; 29: 775–6.
27.
DoganE., UcmakH., SayarliogluH., SahinM., UcarM., GunduzM.Sclerosing encapsulating peritonitis in an anti-HCV-positive patient on chronic ambulatory peritoneal dialysis.Ren Fail2007; 29: 777–8.
28.
GuptaS., WoodrowG.Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen.Clin Nephrol2007; 68: 125–9.
29.
CushmanM., CostantinoJ.P., BovillE.G., WickerhamD.L., BuckleyL., RobertsJ.D.Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial.Br J Haematol2003; 120: 109–16.
30.
CosmanF., Baz-HechtM., CushmanM., VardyM.D., CruzJ.D., NievesJ.W.Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.Thromb Res2005; 116: 1–13.
31.
DobrydnevaY., WeathermanR., TrebleyJ., MorrellM., FitzgeraldM., FichandlerC.Tamoxifen stimulates calcium entry into human platelets.J Cardiovasc Pharmacol2007; 50: 380–90.
